Compare FOFO & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FOFO | NEUP |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | Hong Kong | United States |
| Employees | 14 | 8 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 23.8M |
| IPO Year | N/A | N/A |
| Metric | FOFO | NEUP |
|---|---|---|
| Price | $3.63 | $4.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 51.9K | 44.8K |
| Earning Date | 03-13-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $3.65 |
| 52 Week High | $68.00 | $21.31 |
| Indicator | FOFO | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 62.31 |
| Support Level | $3.78 | $3.85 |
| Resistance Level | $5.74 | $5.18 |
| Average True Range (ATR) | 0.47 | 0.22 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 17.32 | 87.21 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.